Amphastar down 3% after hours on FDA rejection of epinephrine application

Amphastar Pharmaceuticals (NASDAQ:AMPH) slips 3% after hours in reaction to its announcement that it received a “Minor” Complete Response Letter (CRL) from the FDA regarding its marketing application for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose.

It submitted its response yesterday and expects a decision from the agency within three months.

https://seekingalpha.com/news/3535456-amphastar-down-3-after-hours-on-fda-rejection-of-epinephrine-application